Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.37 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAD52 | P43351 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7071736 | 0.84 | KDM4E (0.38) | KDM4EALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL7079153 | 0.80 | CRHR1 (0.36) | KDM4EALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL7981205 | 0.78 | CRHR1 (0.35) | KDM4EALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL7076053 | 0.77 | ADRB1 (0.39) | KDM4EALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL7217519 | 0.77 | CRHR1 (0.53) | CRHR1 | |
| SCHEMBL7071347 | 0.77 | CRHR1 (0.36) | KDM4EALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL7075873 | 0.76 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL7076556 | 0.76 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL7215696 | 0.74 | CRHR1 (0.69) | CRHR1 | |
| SCHEMBL8589875 | 0.73 | CRHR1 (0.36) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670371-B2 | Antagonists of Corticotropin-Releasing Factor | NEUROGEN CORPORATION | 2003-12-30 | — | — | US | disclosed |
| US-20020111490-A1 | Certain pyrrolopyridine derivatives: novel CRF1 specific ligands | NEUROGEN CORPORATION (US) | 2002-08-15 | — | — | US | disclosed |
| US-6362186-B1 | PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2002-03-26 | — | — | US | disclosed |
| US-6355651-B1 | AMINE SUBSTITUTED HETEROCYCLIC COMPOUNDS | NEUROGEN CORPORATION | 2002-03-12 | — | — | US | disclosed |
| US-6291473-B1 | TREATING ANXIETY, DEPRESSION, POST-TRAUMATIC STRESS DISORDER, INFLAMMATORY DISEASES, OBESITY, IN MAMMALS | NEUROGEN CORPORATION | 2001-09-18 | — | — | US | disclosed |
| US-6221875-B1 | TREATING FEEDING DISORDERS, OBESITY, BULIMIA NERVOSA OR HYPERTENSION IN A MAMMAL | NEUROGEN CORPORATION | 2001-04-24 | — | — | US | disclosed |
| US-6147085-A | Aminoalkyl substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives | NEUROGEN CORPORATION (US) | 2000-11-14 | — | — | US | disclosed |
| US-6133282-A | Certain pyrrolopyridine derivatives; novel CRF1 specific ligands | NEUROGEN CORPORATION (US) | 2000-10-17 | — | — | US | disclosed |
| US-5955613-A | Certain pyrrolopyridine derivatives; novel CRF1 specific ligands | NEUROGEN CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
| WO-1998045295-A1 | CERTAIN PYRROLOPYRIDINE DERIVATIVES; NOVEL CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111490-A1 | Certain pyrrolopyridine derivatives: novel CRF1 specific ligands | CRHR1, CRH, CRHR2 | KDM4E 4423/4885ALDH1A1 1934/4885HSD17B10 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.